Mon, Jul 28, 2014, 7:58 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Celldex Therapeutics, Inc. Message Board

  • long_vrts2 long_vrts2 Jul 24, 2013 1:17 AM Flag

    Outstanding review published on GPNMB, CDX-011 featured:

    This is an up-to-date, comprehensive review of GPNMB, its involvement in cancer metastasis and prospects as a therapeutic target in cancer treatment. As I was reading the article, the thought that kept popping up is that CLDX owns GPNMB as a cancer target- an enviable position to be in as GPNMB targeted cancer treatment evolves into a substantial therapeutic segment.

    Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.

    Maric G, Rose AA, Annis MG, Siegel PM.
    Goodman Cancer Research Centre, McGill University, Montréal, Québec, Canada ; Department of Medicine, McGill University, Montréal, Québec, Canada.

    Abstract
    Molecularly targeted therapies are rapidly growing with respect to their clinical development and impact on cancer treatment due to their highly selective anti-tumor action. However, many aggressive cancers such as triple-negative breast cancer (TNBC) currently lack well-defined therapeutic targets against which such agents can be developed. The identification of tumor-associated antigens and the generation of antibody drug-conjugates represent an emerging area of intense interest and growth in the field of cancer therapeutics. Glycoprotein non-metastatic b (GPNMB) has recently been identified as a gene that is over-expressed in numerous cancers, including TNBC, and often correlates with the metastatic phenotype. In breast cancer, GPNMB expression in the tumor epithelium is associated with a reduction in disease-free and overall survival. Based on these findings, glembatumumab vedotin (CDX-011), an antibody-drug conjugate that selectively targets GPNMB, is currently being investigated in clinical trials for patients with metastatic breast cancer and unresectable melanoma. This review discusses the physiological and potential pathological roles of GPNMB in normal and cancer tissues, respectively, and details the clinical advances and challenges in targeting GPNMB-expressing malignancies.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CLDX
13.09-0.48(-3.54%)Jul 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.